China Resources Double-Crane Pharmaceutical Co Ltd Intrinsic Valuation and Fundamental Analysis - China Resources Double-Crane Pharmaceutical Co Ltd

C	China Resources Double-Crane Pharmaceutical Co Ltd SSE:600062	CN
B	Bonyan REIT Fund SAU:4347	SA
	Hannan Metals Ltd XTSX:HAN	CA

Intrinsic Value

The intrinsic value for China Resources Double-Crane Pharmaceutical Co Ltd (600062) under the Base Case is 21.57 CNY. Compared with the current market price of 16.07 CNY, the stock appears Undervalued by 26% .

Intrinsic value calculated using Multiples

¥21.57

Other reference points

DCF valuation

¥25.73

Wall St target

¥24.79

Do our valuations actually work? See backtest results .

Intrinsic Value

Undervaluation 26%

Intrinsic Value

Price ¥16.07

C

Loading...

What is Valuation History?

Track Buy Zone

20% below Intrinsic Value ¥17.26

Get notified when the price drops into your buy zone

Intrinsic Value ¥21.57

Margin of Safety 20% ¥17.26

Current Price ¥16.07

Or choose another margin of safety

0% below Intrinsic Value

10% below Intrinsic Value

30% below Intrinsic Value

40% below Intrinsic Value

50% below Intrinsic Value

Custom

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations

Let our AI break down the key assumptions behind the intrinsic value calculation for China Resources Double-Crane Pharmaceutical Co Ltd.

Explain Valuation